Publications

Publications Co-Authored by Lundbeck Scientists

Our commitment to science is reflected in our track record of publications. Here are the most recent publications co-authored by Lundbeck scientists.

Article       Product      Authors      Publication links
Assessing and managing medication overuse headache in Australian clinical practice   Eptinezumab   Wijeratne T, Jenkins B, Stark R, Sun-Edelstein C   Read publication
Assessment of patient life engagement in major depressive disorder using items from the Inventory of Depressive Symptomatology Self-Report (IDS-SR)   Brexpiprazole   Thase M, Ismail Z, Meehan S, Weiss C, Regnier S, Larsen K, McIntyre R   Read publication
Burden of medication overuse in migraine: A cross-sectional population-based study in five European countries using the 2020 National Health and Wellness Survey (NHWS)   Eptinezumab   Dissing A, Lee XY, Osterberg O, Hammer-Helmich L   Read publication
Changes in metabolic parameters and body weight in patients with prediabetes treated with adjunctive brexpiprazole: pooled analysis of short- and long-term clinical studies in major depressive disorder   Brexpiprazole   Newcomer JW, Meehan SR, Chen D, Brubaker M,  Weiss C   Read publication
Clinical benefits of vortioxetine 20 mg/day in patients with major depressive disorder   Vortioxetine   Christensen MC, McIntyre R, Adair M, Florea I,  Loft H, Fagiolini A   Read publication
Design and implementation of a digitally enabled care pathway to improve management of depression in a large health care system: Protocol for the implementation of a patient care platform   Vortioxetine   Khatib R, McCue M, Blair C, Roy A, Franco J, Fehnert B, King J, Sarkey S, Chrones L, Martin M, Kabir C, Kemp D   Read publication
Design of a real-world, prospective, longitudinal, observational study to compare vortioxetine with other standard of care antidepressant treatments in patients with major depressive disorder: a PatientsLikeMe survey   Vortioxetine   Raveendran S, Singh D, Burke MC, McAuliffe-Fogarty AH, Parikh SV, McIntyre RS, Roy A, Martin M, Chrones L, Opler M, Blair C, McCue M   Read publication
Does ethnicity impact CYP2D6 genotype–phenotype relationships?   Brexpiprazole   Frederiksen T, Areberg J, Schmidt E, Stage TB, Brøsen K   Read publication
Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: The MEMORY study   Vortioxetine   Christensen MC, Schmidt SN,  Grande I   Read publication
Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: post hoc analysis of Inventory of Depressive Symptomatology Self-Report data   Brexpiprazole   McIntyre RS, Therrien F, Ismail Z, Meehan SR, Miguelez M, Larsen KG, Chen D, MacKenzie EM, Thase ME   Read publication
Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial   Eptinezumab   Starling AJ, Cowan R, Buse D, Diener HC, Marmura MJ, Hirman J, Brevig T, Cady R   Read publication
Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial   Eptinezumab   Jönsson L, Regnier SA, Kymes S, Awad SF, Talon B, Lee, XY, Goadsby P     Read publication
Head-to-head comparison of vortioxetine versus desvenlafaxine in patients with major depressive disorder with partial response to SSRI monotherapy: results of the VIVRE study   Vortioxetine   McIntyre RS, Florea I, Pedersen MM, Christensen MC   Read publication
Improving to Four or Fewer Monthly Headache Days Per Month Provides a Clinically Meaningful Therapeutic Target for Patients with Chronic Migraine   Eptinezumab   Kaniecki R, Friedman D, Asher D, Hirman J, Cady R   Read publication
Risk factors for migraine disease progression: a narrative review for a patient-centered approach   Eptinezumab   Lipton R, Buse D, Diener H, Nahas S, Tietjen G, Martin V, Löf E, Brevig T   Read publication
Longitudinal study to assess antidepressant treatment patterns and outcomes in individuals with depression in the general population   Vortioxetine   Ohayon M, McCue M, Krystal A, Selzler K, Chrones L, Lawrence DF, Côté M   Read publication
Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experiment   Eptinezumab   Schwedt T, Martin A, Kymes S, Talon B, Lee X, Cady R, Asher D, Karnik-Henry M, Mulvihill E, Bates D, Beusterien K   Read publication
Placebo effects in clinical trials of anti-CGRP monoclonal antibodies for migraine prevention   Eptinezumab   Regnier S, Lee XY   Read publication
Population pharmacokinetic analysis of brexpiprazole to support its indication and dose selection in adolescents with schizophrenia   Brexpiprazole   Wang Y, Wang X, Larsen F, Cahill D, Zoubroulis A, Ward C, Kohegyi E, Raoufinia A   Read publication
Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients with Schizophrenia in a Randomized, Parallel-Arm, Pivotal Study   Aripiprazole   Such P, Yildirim M, Madera-McDonough J, Harlin M, Larsen F, Zhang Z, Citrome L   Read publication
The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in patients with schizophrenia: real-world evidence from US claims data   Aripiprazole   Waters HC, Stellhorn R, Touya M, Chen M, Fitzgerald H, Bhattacharjee S, Citrome L   Read publication
Treatment with eptinezumab for migraine prevention in people with chronic migraine and medication-overuse headache: A Plain Language Summary   Eptinezumab   Starling A, Kolbet, M, Cady R, Brevig   Read publication
User-centered design of a digitally enabled care pathway in a large health system: Qualitative interview study   Vortioxetine   McCue M, Khatib R, Kabir C, Blair C, Fehnert B, King J, Spalding A, Zaki L, Chrones L, Roy A, Kemp D   Read publication
Using Artificial Intelligence With Natural Language Processing to Identify Patients With Migraine, Migraine-Associated Symptoms, and Migraine Medication Use Within Electronic Health Records   Eptinezumab   D Riskin, R Cady, A Shroff, N Hindiyeh, T Smith, S Kymes   Read publication
A Randomized, Open‑Label, Multiple‑Dose, Parallel‑Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2‑Month Long‑Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder   Aripiprazole
  Harlin M, Yildirim M, Such P, Madera-McDonough J, Jan M, Jin N, Watkin S, Larsen F
  Read publication
Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: protocol for RESOLUTION – a phase 4, multi-national, randomised, double-blind, placebo-controlled study
  Eptinezumab
  Jensen R, Schytz H, Tassorelli C, Terwindt G, Carlsen L, Mittoux A, Osterberg O, Lipton R, Tepper S, Blumenfeld A, Lundqvist C,
  Read publication
Alternative Indirect Treatment Comparisons for Eptinezumab in Episodic and Chronic Migraine Prevention
  Eptinezumab
  Fawsitt C, Thom H, Regnier S, Lee X, Kymes S, Vase L
  Read publication
An exploratory database study of factors influencing the continuation of brexpiprazole treatment (prescription) in patients with schizophrenia using information from psychiatric electronic medical records processed with natural language processing system   Brexpiprazole
  Iyo M, Akiyoshi H, Sekine D, Shibasaki Y, Mamiya N
  Read publication
Aripiprazole plasma concentrations delivered from two 2-month long-acting injectable formulations: an indirect comparison
  Aripiprazole
  Fitzgerald H, Saklad SR, Chepke C, Harlin M, Larsen F, Chumki S, Such P, Yildirim M, Panni M, Madera-McDonough J
  Read publication
Considerations when selecting an antidepressant: a narrative review for primary care providers treating adults with depression
  Vortioxetine
  Montano BC, Jackson CW, Vanacore D, Weisler R
  Read publication
Disease-Specific Quality of Life Measures Mapped to the EQ-5D in Patients with Migraine: A Post Hoc Analysis of the DELIVER Trial
  Eptinezumab
  Jönsson L, Regnier SA, Kymes S, Awad SF,Talon B, Lee, XY, Goadsby P
  Read publication
Does ethnicity impact CYP2D6 genotype–phenotype relationships?
  Vortioxetine
  Frederiksen T, Areberg J, Schmidt E, Stage TB and Brøsen K
  Read publication
Early Clinical Experience With Eptinezumab: Results of a Retrospective Observational Study of Patient Response in the United States
  Eptinezumab
  Starling A, Kymes S, Asher D, Soni-Brahmbhatt S, Karnik-Henry M
  Read publication
Effectiveness of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: US Cohort Results From the Global RELIEVE Study
  Vortioxetine
  Mattingly G, Brunner E, Chrones L, Lawrence DF, Simonsen K, Ren H
  Read publication
Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer's disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea
  Vortioxetine
  Cumbo E, Adair M, Åstrom DO, Christensen MC
  Read publication
Efficacy and Safety of Eptinezumab for Migraine Prevention in Patients With Documented Prior Preventive Treatment Failures: Subgroup Analysis of the Randomized, Placebo-Controlled DELIVER Trial
  Eptinezumab
  Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen L, Josiassen MK, Phul R, Sperling B
  Read publication
Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures
  Eptinezumab
  Goadsby PJ, Barbanti P, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B
  Read publication
Eptinezumab Improved Patient-Reported Outcomes in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
  Eptinezumab
  Starling AJ, Cowan R, Cady R
  Read publication
Eptinezumab Improved Patient-Reported Outcomes in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
  Eptinezumab
  Starling AJ, Buse D, Cowan R, Diener HC, Marmura MJ, Hirman J, Brevig T, Freeman E, Cady R
  Read publication
The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study
  Eptinezumab
  Rasmussen N, Deligianni C, Christensen C, Karlsson W, Al-Khazali H, Van de Casteele T, Granhall C, Amin F, Ashina M
  Read publication
Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies
  Vortioxetine
  Mattingly GW, Necking O, Schmidt SN, Reines E, Ren H
  Read publication
Mental health diagnoses and services utilization vary by wage level
  Vortioxetine
  Sherman B, Lawrence D, Kuharic M, Chrones L, Patel S, Touya M
  Read publication
Patient Preferences for Attributes of Advanced Migraine Prevention Medications: Findings From a Discrete Choice Experiment
  Eptinezumab
  Schwedt T, Martin A, Kymes S, Talon B, Lee X, Cady R, Asher D, Karnik-Henry M, Mulvihill E, Bates D, Beusterien K
  Read publication
Relationships Between Headache Frequency, Disability, and Disability-Related Unemployment Among Adults with Migraine
  Eptinezumab
  Shapiro R, Martin A, Bhardwaj S, Thomson H, Maculaitis M, Anderson C, Kymes S
  Read publication
Safety and effectiveness of vortioxetine for major depressive disorder: real-world evidence from a population-based study in South Korea
  Vortioxetine
  Moon SW, Kim JW, Kim DH, Lee KY, Reines EH, Lee M, Park YJ
  Read publication
Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients with Bipolar I Disorder in a Randomized, Parallel-Arm, Pivotal Study
  Aripiprazole
  McIntyre RS, Larsen F, Madera-McDonough J, Such P, Yildirim M, Zhang Z, Harlin M
  Read publication
Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability
  Vortioxetine
  Adair M, Christensen MC, Florea I, Loft H, Fagiolini A
  Read publication
Alternative Indirect Treatment Comparisons for Eptinezumab in Episodic and Chronic Migraine Prevention   Eptinezumab   Fawsitt C, Thom H, Regnier S, Lee X, Kymes S, Vase L   Read publication
Assessing reliability and validity of the oxford depression questionnaire (ODQ) in a Japanese clinical population   Vortioxetine   Kato M, Kikuchi T, Watanabe K, Sumiyoshi T, Moriguchi Y, Åström DO, Christensen MC   Read publication
Brexpiprazole for the Treatment of Agitation in Alzheimer’s Dementia: A Randomized Clinical Trial   Brexpiprazole   Lee D, Slomkowski M, Hefting N, Chen D, Larsen K, Kohegyi E, Hobart M, Cummings J, Grossberg G   Read publication
Burden of migraine in a cohort of newly diagnosed or recurrent patients in Alberta, Canada   Eptinezumab   Cowling T, Graves E, McMullen S, Ekwaru P, Pham T, Mayer M, Ladouceur M, Hubert M, Bougie J, Amoozegar F   Read publication
Clinical benefits and bioequivalence of vortioxetine oral drop solution versus oral tablets   Vortioxetine   Fagiolini A, Adair M, Petersen KB, Areberg J, Christensen MC   Read publication
Comparison of indirect treatment methods in migraine prevention to address differences in mode of administration   Eptinezumab   Fawsitt C, Thom H, Regnier S, Lee X, Kymes S, Vase L   Read publication
Decreased step count prior to the first visit for MDD treatment: a retrospective, observational, longitudinal cohort study of continuously measured walking activity obtained from smartphones   Vortioxetine   Fujino Y, Tokuda F, Fujimoto S   Read publication
Disease-Specific Quality of Life Measures Mapped to the EQ-5D in Patients with Migraine: A Post Hoc Analysis of the DELIVER Trial   Eptinezumab   Jönsson L, Regnier SA, Kymes S, Awad SF,Talon B, Lee, XY, Goadsby P     Read publication
Dynamic extracellular vestibule of human SERT: unveiling druggable potential with novel high-affinity allosteric inhibitors   N/A   Salomon K, Abramyan A, Plenge P, Wang L, Bang-Andersen B, Loland C, Shi L   Read publication
Efficacy and safety of eptinezumab in adults with a dual diagnosis of chronic migraine and medication-overuse headache (SUNLIGHT): a randomized, double-blind, parallel-group, placebo-controlled, phase 3 study   Eptinezumab   Yu S, Zhou J, Luo G, Xiao Z, Ettrup A, Jannson G, Florea I, Pozo-Rosich P   Read publication
Exploring depression in Alzheimer’s disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management   Vortioxetine   Padovani A, Antonini A, Barone P, Bellelli G, Fagiolini A, Strambi LF, Sorbi S, Stocchi F   Read publication
Exploring depression in Parkinson ’s disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management.   Vortioxetine   Stocchi F, Antonini A, Barone P, Bellelli G, Fagiolini A,  Ferini Strambi L, Marra C,    Sorbi S, Padovani A   Read publication
Long-term Effectiveness of Eptinezumab in Patients With Migraine and Prior Preventive Migraine Treatment Failures   Eptinezumab   Ashina M, Starling A, Tepper S, Gendolla A, Sperling B, Ettrup A, Josiassen M   Read publication
Meta-regression to explain the placebo effects in clinical trials of anti-CGRP monoclonal antibodies for migraine prevention   Eptinezumab   Regnier S, Lee XY   Read publication
Pharmacokinetics and Safety of Eptinezumab in Healthy Chinese Participants: A Randomized Clinical Trial   Eptinezumab   Li X, Xu H, Cui E, Peterson K, Ryding J, Ettrup A, Ostergaard J, Larsen K   Read publication
Placebo effects in clinical trials of anti-CGRP monoclonal antibodies for migraine prevention   Eptinezumab   Regnier S, Lee XY   Read publication
Prioritizing Treatment Goals in Bipolar I Disorder: Results from a US Patient Survey Using a Best–Worst Scaling   Aripiprazole   Bridges JFP, Goldberg J, Fitzgerald HM, Chumki S, Beusterien K, Will O, Citrome L     Read publication
Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study   Vortioxetine   McDaniel BT, Cornet V, Carroll J, Chrones L, Chudzik J, Cochran J, Guha S, Lawrence DF, McCue M, Sarkey S, Lorenz B, Fawver J   Read publication
Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial   Eptinezumab   Ashina M, Lipton R, Ailani J, Versijpt J, Sacco S, Dimos-Dimitrios M, Christoffersen CL, Sperling B, Ettrup A   Read publication

 

Article       Product      Authors      Publication links
A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder
  Vortioxetine
  Bose R, Hamdani SU, Minhas FA, Herr KJ
  Read publication
A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia
  N/A
  Meyer-Lindenberg A, Nielsen J, Such P, Lemming O, Zambori J, Buller R, von der Goltz C
  Read publication
A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of L-Dopa-induced dyskinesia
  N/A
  Calabrese V, Picconi B, Heck N, Campanelli F, Natale G, Marino G, Sciaccaluga M, Ghiglieri V, Tozzi A, Anceaume E, Cuoc E, Caboche J, Conquet F, Calabresi P, Charvin D
  Read publication
A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease
  N/A
  Rascol O, Medori R, Baayen C, Such P, Meulien D
  Read publication
Activity-State Dependent Reversal of Ketamine-Induced Resting State EEG Effects by Clozapine and Naltrexone in the Freely Moving Rat
  N/A
  Bowman C, Richter U, Jones C, Agerskov C, Frisch Herrik K
  Read publication
Adherence to, and persistence of, antidepressant therapy in patients with major depressive disorder: results from a population-based study in Italy
  Vortioxetine
  Di Nicola M, Dell’Osso B, Peduto I, Cipelli R, Pugliese AC, Signorelli MS, Ventriglio A, Martinotti G
  Read publication
Advancing 89Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - The choice of chelator is essential
  N/A
  Wuensche T, Stergiou N, Mes I, Verlaan M, Schreurs M, Kooijman E, Janssen B, Windhorst A, Jensen A, Asuni A, Bang-Andersen B, Beaino W, Dongen G, Vugts D
  Read publication
An app-based digit symbol substitution test for assessment of cognitive deficits in adults with major depressive disorder: evaluation study
  Vortioxetine
  McIntyre RS, Lipsitz O, Rodrigues NB, Subramaniapillai M, Nasri F, Lee Y, Fehnert B, King J, Chrones L, Kratiuk K, Uddin S, Rosenblat JD, Mansur RB, McCue M
  Read publication
Antidepressant prescription for major depressive disorder: results from a population-based study in Italy
  Vortioxetine
  Dell’Osso B, Di Nicola M, Cipelli R, Peduto I, Pugliese AC, Signorelli M, Ventriglio A, Martinotti G
  Read publication
Antipsychotic treatment patterns in Alzheimer's disease patients with agitation: a cohort study using the UK clinical practice research datalink
  Brexpiprazole
  Tran CT, Bøg M, CollingsSL, Johnson M, Qizilbash N, Lind S, Baker RA, Jørgensen KT
  Read publication
Apo and ligand-bound high resolution Cryo-EM structures of the human Kv3.1 reveal a novel binding site for positive modulators
  N/A
  Botte M, Huber S, Bucher D, Klint J, Rodríguez D, Tagmose L, Chami M, Cheng R, Hennig M, Rahman W
  Read publication
Association between baseline cognitive symptoms and the subsequent presenteeism and global function in patients with major depressive disorder
  Vortioxetine
  Watanabe K, Marumoto T, Ge H, Moriguchi Y, Fujikawa K, Fernandez JL
  Read publication
Association between CYP2D6 metabolizer status and vortioxetine exposure and treatment switching: a retrospective, naturalistic cohort study using therapeutic drug monitoring data from 640 patients
  Vortioxetine
  Frederiksen T, Smith RL, Jukic MM, Molden E
  Read publication
Behavioral encoding across timescales by region-specific  dopamine dynamics
  N/A
  Jørgensen S,Ejdrup A, Lycas M, Posselt L, Tian L, Dreyer J, Herborg F, Sørensen A, Gether U
  Read publication
Changes in Acute Headache Medication Use Among Patients With Chronic Migraine: Subanalysis of PROMISE-2
  Eptinezumab
  Cowan RP, Marmura MJ, Diener HC, Starling A, Schim J, Hirman J, Brevig T, Cady R
  Read publication
Characterizing mood disorders in the AFFECT study: a large, longitudinal, and phenotypically rich genetic cohort in the US
  N/A   Dalby M, Vitezic M, Plath N, Hammer-Helmich L, Jiang Y, Tian C, Dhamija D, Wilson C, Hinds D, 23andMe Research Team, Sullivan P, Buckholtz J, Smoller J
  Read publication
Characterizing Mood Disorders in the AFFECT study: A Large, Longitudinal, and Phenotypically Rich Genetic Cohort in the US
  N/A
  Dalby M, Vitezic M, Plath N, Hammer-Helmich L, Jiang Y, Tian C, Dhamija D, Wilson C, Hinds D, 23andMe Research Team, Sullivan P, Buckholtze J, Smollerg J
  Read publication
Characterizing primary care for patients with major depressive disorder using electronic health records of a US-based healthcare provider
  Vortioxetine
  Larson S, Nemoianu A, Lawrence DF, Troup M, Gionfriddo M, Pousti B, Sun H, Riaz F, Wagner E, Chrones L, Touya M
  Read publication
Chronic Stress Induces Hippocampal Mitochondrial Damage in APPPS1 Model Mice and Wildtype Littermates
  N/A
  Clement A, Madsen M, Kastaniegaard K, Wiborg O, Asuni A, Stensballe A
  Read publication
Development and validation of a novel model for characterizing migraine outcomes within real-world data
  Eptinezumab
  Hindiyeh NA, Riskin D, Alexander K, Cady R, Kymes S
  Read publication
Disease progression in Multiple System Atrophy ─ Novel modelling framework and predictive factors
  N/A
  Kühnel L, Raket L, Åström D, Berger A-K, Helbech Hansen I, Krismer F, Wenning G, Seppi K, Poewe W, Molinuevo JL on behalf of the EMSA-SG natural history study investigators
  Read publication
Diseases prevalent before major depressive disorder diagnosis: an exploratory nested case–control study using health insurance-based claims data
  Vortioxetine
  Cho Y, Mishiro I, Akaki T, Akimoto T, Fujikawa K
  Read publication
Distal kinetic deuterium isotope effect: Phenyl ring deuteration attenuates N-demethylation of Lu AF35700
  N/A
  Jensen K, Christoffersen C, Didriksen M, Jørgensen M
  Read publication
Durability of the Clinical Benefit of Droxidopa for Treatment of Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment
  Droxidopa
  R Hauser, Gorny S, Hewitt, LA, Lindsten A, Kymes S, Favit A, Isaacson S
  Read publication
Early Response to Eptinezumab Indicates High Likelihood of Continued Response in Patients with Chronic Migraine
  Eptinezumab
  Buse DC, Winner PK, Charleston LC, Hirman J, Cady R, Brevig T
  Read publication
Effectiveness and safety of Vortioxetine for major depressive disorder in real-world clinical practice: results from the single-arm RELIEVE China study
  Vortioxetine
  Wang G, Xiao L, Ren H, Simonsen K, Ma J, Xu X, Guo P, Wang Z, Bai L, Reines EH, Hammer-Helmich L
  Read publication
Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study
  Vortioxetine
  Almeida SS, Christensen MC, Simonsen K, Adair M
  Read publication
Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: results of the RECONNECT study
  Vortioxetine
  Christensen MC, Schmidt S, Grande I
  Read publication
Effectiveness of vortioxetine in patients with major depressive disorder in real-world clinical practice in Italy: results from the RELIEVE study
  Vortioxetine
  De Filippis S, Pugliese A, Christensen MC, Rosso G, Di Nicola M, Simonsen K, Ren H,
  Read publication
Effectiveness of vortioxetine in patients with major depressive disorder in real-world clinical practice: French cohort results from the global RELIEVE study
  Vortioxetine
  Polosan M, Rabbani M, Christensen MC, Simonsen K, Ren H
  Read publication
Effectiveness of vortioxetine in patients with major depressive disorder in real-world clinical practice: results of the RELIEVE study
  Vortioxetine
  Mattingly G, Ren H, Christensen MC, Katzman MA, Polosan M, Simonsen K, Hammer-Helmich L
  Read publication
Effects of brexpiprazole on functioning in patients with schizophrenia: post hoc analysis of short- and long-term studies
  Brexpiprazole
  Correll CU, Shi L, Therrien F, MacKenzie E, Meehan SR, Weiss C, Hefting N, Hobart M
  Read publication
Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study
  Eptinezumab
  Barbanti P, Goadsby PJ, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B
  Read publication
Efficacy and safety of eptinezumab for migraine prevention in patients with 2–4 prior preventive treatment failures: a randomized, double-blind, placebo-controlled, phase 3b study
  Eptinezumab
  Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen L, Josiassen MK, Phul R, Sperling B
  Read publication
Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
  Eptinezumab
  Ashina M, McAllister P, Cady R, Hirman J, Ettrup A
  Read publication
Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness
  Vortioxetine
  Baldwin DS, Necking O, Schmidt SN, Ren H, Reines EH
  Read publication
Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: a post hoc analysis of four clinical studies
  Brexpiprazole
  Katzman M, Therrien F, MacKenzie E, Wang F, de Jong-Laird A, Boucher M
  Read publication
Emotional blunting in patients with depression. Part I: clinical characteristics
  Vortioxetine
  Christensen MC, Ren H, Fagiolini A
  Read publication
Emotional blunting in patients with depression. Part II: relationship with functioning, well‑being, and quality of life
  Vortioxetine
  Christensen MC, Ren H, Fagiolini A
  Read publication
Emotional blunting in patients with depression. Part III: relationship with psychological trauma
  Vortioxetine
  Christensen MC, Ren H, Fagiolini A
  Read publication
Epidemiology and treatment utilization for Canadian patients with migraine: a literature review
  Eptinezumab
  Graves E, Gerber B, Berrigan P, Shaw E, Cowling T, Ladouceur MP, Bougie J,
  Read publication
Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies
  Eptinezumab
  Baker B, Shen V, Cady R, Ettrup A, Larsen F
  Read publication
Eptinezumab for migraine prevention in patients 50 years or older
  Eptinezumab
  Martin V, Tassorelli C, Ettrup A, Hirman J, Cady R
  Read publication
Eptinezumab Treatment Initiated During a Migraine Attack is Associated with Meaningful Improvement in Patient-Reported Outcome Measures: Secondary Results From the Randomized Controlled RELIEF Study
  Eptinezumab
  McAllister P, Winner PK, Ailani J, Buse DC, Lipton RB, Chakhava G, Josiassen MK, Lindsten A, Mehta L, Ettrup A, Cady R
  Read publication
Estimating the In Vivo Function of CYP2D6 Alleles through Population Pharmacokinetic Modelling of Brexpiprazole
  Brexpiprazole
  Frederiksen T, Areberg J, Raoufinia A, Schmidt E, Bjerregaard Stage T, Brøsen K
  Read publication
Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention
  Eptinezumab
  Lipton R, Goadsby P, Dodick D, McGinley J, Houts C, Wirth RJ, Kymes S, Ettrup A, Østerberg O, Cady R, Ashina M, Buse D
  Read publication
Exploring life engagement from the perspective of patients with major depressive disorder: a study using patient interviews
  Brexpiprazole
  Therrien F, Meehan S, Weiss C, Dine J, Brown T, MacKenzie E
  Read publication
Further validation of the THINC-it tool and extension of the normative data set in a study of n = 10.019 typical controls
  N/A
  Dalby M, Annas P, Harrison JE
  Read publication
Health-related quality of life over 6 months in patients with major depressive disorder who started antidepressant monotherapy
  Vortioxetine
  Noto S, Wake M, Mishiro I, Hammer-Helmich L, Ren H, Moriguchi Y, Fujikawa K, Fernandez J
  Read publication
Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2
  Eptinezumab
  Martin V, Nagy J, Janelidize M, Giorgadze G, Hirman J, Cady R, Mehta L., Buse D,
  Read publication
Impact of depression onset and treatment on the trend of annual medical costs in Japan: an exploratory, descriptive analysis of employer-based health insurance claims data
  Vortioxetine
  Cho Y, Mishiro I, Fujimoto S, Nakajima T
  Read publication
Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data
  Vortioxetine
  Touya M, Lawrence D, Kangethe A, Chrones L, Evangelatos T, Polson M
  Read publication
Indirect Meta-Analysis of Brexpiprazole Versus Aripiprazole in the Acute Treatment of Schizophrenia
  Brexpiprazole
  Seifritz E, Friede M, Schnitker J
  Read publication
Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials
  Eptinezumab
  Anderson C, Brunner E, Cady R, Hirman J, Ogbru A, McGill L, Schim J
  Read publication
Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab
  Eptinezumab
  Blumenfeld A, Ettrup A, Hirman J, Ebert B, Cady R
  Read publication
Lu AG64066 for Tourette Syndrome in adults.
  N/A
  Mueller-Vahl K; TBD
  Read publication
Measuring Dose-Related Efficacy of Eptinezumab for Migraine Prevention: Post Hoc Analysis of PROMISE-1 and PROMISE-2   Eptinezumab   Apelian R, Boyle L, Hirman J, Asher D   Read publication
Mental healthcare resource utilization following initiation of aripiprazole 400mg long-acting injectable: a retrospective real-world study   Aripiprazole   Waters HC, Touya M, Wee SN, Ng M, Thadani S, Surendran S, Rentería M, Rush AJ, Patel R, Sarkar J, Fitzgerald HM, Chen M, Han X   Read publication
Mobile app to enhance patient activation and patient-provider communication in major depressive disorder management: collaborative, randomized controlled pilot study   Vortioxetine   McCue M, Blair C, Fehnert B, King J, Cormack F, Sarkey S, Eramo A, Kabir C, Khatib R, Kemp D   Read publication
Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study   Eptinezumab   Cady R, Lipton R, Buse D, Josiassen MK, Lindsten A, Ettrup A   Read publication
Patient preference for early onset of efficacy of preventive migraine treatments   Eptinezumab   Ailani J, Winner P, Hartry A, Brevig T, Bøg M, Blædel Lassen A, Marsh K, Cutts K, Le Lay A   Read publication
Patient-centricity and sensitivity to change of the unified MSA rating scale subitems: a data-driven analysis   N/A   Krismer F, Seppi K, Jönsson L, Åström D, Berger A-K, Simonsen J, Wenning G,  Poewe W on behalf of EMSA-SG NHS Investigatorsa, Rasagiline-for-MSA investigatorsa   Read publication
Patient-Identified Burden and Unmet Needs in Patients With Cluster Headache: An Evidence-Based Qualitative Literature Review   Eptinezumab   Freeman E, Adair M, Beeler D, Casper R, Herman MP, Reeves D, Reinsch S   Read publication
Patient-reported outcome measures for life engagement in mental health: a systematic review   Brexpiprazole   McIntyre RS, Ismail Z, Watling CP, Weiss C, Meehan SR, Oberdhan D, Musingarimi P, Thase ME   Read publication
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials   Eptinezumab   Lipton RB, Charleston L, Tassorelli C, Brevig T, Hirman J, Cady R   Read publication
PET as a translational tool in drug development for Neuroscience compounds   Vortioxetine   Varrone A, Bundgaard C, Bang-Andersen B   Read publication
PET as a translational tool in drug development for Neuroscience compounds   N/A   Varrone A, Bundgaard C, Bang-Andersen B   Read publication
Polygenic heterogeneity in antidepressant treatment and placebo response   Vortioxetine   Nøhr AK, Forsingdal A, Moltke I, D. Howes OD, Vitezic M, Albrechtsen A, Dalby M   Read publication
Population Pharmacokinetic Modeling and Exposure-Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia   Aripiprazole   Wang X, Raoufinia A, Bihorel S, Passarell J, Mallikaarjun S, Phillips L   Read publication
Practical advice for primary care clinicians on the safe and effective use of vortioxetine for patients with major depressive disorder (MDD)   Vortioxetine   Montano  B, Jackson C, Vanacore D, Weisler R   Read publication
Prediction of residual cognitive disturbances by early response of depressive symptoms to antidepressant treatments in patients with major depressive disorder   Vortioxetine   Sumiyoshi T, Hoshino T, Mishiro I, Hammer-Helmich L, Ge H, Moriguchi Y, Fujikawa K, Fernandez J   Read publication
Psychometric Validation of a Patient-Reported Single-Item Assessment of “Good Day Bad Day” in a Neurogenic Orthostatic Hypotension Population Treated With Droxidopa   Droxidopa   François C, Kymes S, Hewitt LA, Germain N, Majewska R, Taieb V   Read publication
Psychometric Validation of a Patient-Reported Single-Item Assessment of “Good Day Bad Day” in a Neurogenic Orthostatic Hypotension Population Treated With Droxidopa   Droxidopa   Francois C, Germain N, Majewska R, Taieb V, Hewitt LA,  Kymes   Read publication
Rapid Resolution of Migraine Symptoms After Initiating the Preventive Treatment Eptinezumab During a Migraine Attack: Results from the Randomized RELIEF Trial   Eptinezumab   Ailani J, McAllister P, Winner PK Chakhava G, Josiassen MK, Lindsten A, Sperling B, Ettrup A, Cady R   Read publication
Readmissions, Costs, and Predictors of Time to Outpatient Follow-Up After Discharge Among Medicaid Beneficiaries Utilizing Oral versus Long-Acting Injectable Antipsychotics in Bipolar Disorder or Schizophrenia   Aripiprazole   Tidmore LM; Keast SL; Waters HC; Pareja KL; Cothran T; Skrepnek GH   Read publication
Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects   Vortioxetine   Papalexi E, Galanopoulos A, Kontis D, Markopoulou M, Balta G, Karavelas E, Panagiotidis P, Vlachos T, Ettrup A         Read publication
Reduction in Migraine-Associated Burden After Eptinezumab Treatment in Patients With Chronic Migraine   Eptinezumab   McAllister P, Kudrow D, Cady R, Hirman J, Ettrup A   Read publication
Remote Assessment of Disease and Relapse in Major Depressive Disorder (RADAR-MDD): Recruitment and retention in a longitudinal remote measurement study   N/A   Matcham F, Leightley D, Siddi S, Lamers F, White KM, Annas P, de Girolamo G, Difrancesco S, Haro JM, Horsfall M, Ivan A, Lavelle G, Li Q, Lombardini F, Mohr DC, Narayan V, Oetzmann C, Penninx BWJH, Simblett S, Wykes T, PAB member, Brasen C, Myin-Germeys I, Rintala A, Dobson R, Folarin A, Ranjan Y, Cummins N, Manyakov N, Vairavan S, Hotopf M, on behalf of the RADAR-CNS consortium   Read publication
Residual cognitive and psychosocial functional impairment in outpatients in Greece who responded to conventional antidepressant monotherapy treatments for major depressive disorder (MDD)   Vortioxetine   Papalexi E, Galanopoulos A, Roukas D, Argyropoulos I, Michopoulos I, Douzenis A, Gkolia I, Fotiadis P, Kontis, Zervas IM   Read publication
Risk of major depressive disorder in adolescent and young adult cancer patients in Japan   Vortioxetine   Akechi T, Mishiro I, Fujimoto S   Read publication
Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies   Eptinezumab   Pozo-Rosich P, Dodick D, Ettrup A, Hirman J, Cady R   Read publication
The Economic Burden of Post-Traumatic Stress Disorder in the United States from a Societal Perspective   Brexpiprazole   Davis L, Schein J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Urganus A, Guerin A, Lefebvre P, Houle C   Read publication
The effect of combined dexmedetomidine and  isoflurane anaesthesia on visually evoked  responses in rats – an electrophysiological study   N/A   Østergaard F, Skoven CS, Laursen B, Dyrby T, Wade A   Read publication
The effect of combined dexmedetomidine and isoflurane anaesthesia on visually evoked responses in rats – an electrophysiological study   N/A   Østergaard F, Laursen B, Christensen K et al   Read publication
The Motivation and Energy Inventory (MEI): Analysis of the clinically relevant response threshold in patients with major depressive disorder and emotional blunting using data from the COMPLETE study   Vortioxetine   Christensen MC, Adair M, Loft H, McIntyre R   Read publication
The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach   Aripiprazole   Correll C, Chepke C, Gionfriddo P, Parks J, Foxworth P, Basu A, Brister T, Brown D, Clarke C, Hassoun Y   Read publication
Therapeutic potential of vortioxetine for anhedonia-like symptoms in depression: a post hoc analysis of data from a clinical trial conducted in Japan   Vortioxetine   Watanabe K, Fujimoto S, Marumoto T, Kitagawa T, Ishida K, Nakajima T, Moriguchi Y, Fujikawa K, Inoue T   Read publication
Townsend et al. Antipsychotic-Related Stigma and the Impact on Treatment Choices: A Systematic Review and Framework Synthesis   Brexpiprazole   Townsend M, Houle C, Mose TN, Pareja K, Waters H, Brubaker M, Buchanan-Hughes A, Worthington E, Pritchett D     Read publication
Treatment Discontinuation Among Patients with Schizophrenia Treated with Brexpiprazole and Other Oral Atypical Antipsychotics in Japan: A Retrospective Observational Study   Brexpiprazole   Hishimoto A, Yasui-Fukukori N, Sekine D, Matsukawa M, Yamada S   Read publication
Validation and functional relevance of the short form of the perceived deficits questionnaire for depression for Japanese patients with major depressive disorder   Vortioxetine   Sumiyoshi T, Uchida H, Watanabe K, Oosawa M, Ren H, Moriguchi Y, Fujikawa K, Fernandez J   Read publication
Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study   Vortioxetine   Thase M, Jacobsen P, Hanson E, Xu R, Tolkoff M, Murthy V   Read publication
Vortioxetine for major depressive disorder in adolescents: 12-week randomized, placebo-controlled, fluoxetine-referenced, fixed-dose study   Vortioxetine   Findling RL, DelBello M, Zuddas A, Emslie GJ, Ettrup A, Petersen ML, Schmidt SN, Rosen M   Read publication

 

Article      Product      Authors      Publication links      Journal
A large-scale genome-wide gene expression analysis in peripheral blood identifies very few differentially expressed genes related to antidepressant treatment and response in patients with Major Depression Disorder   Vortioxetine   Nøhr AK, Lindow M, Forsingdal A, Demharter S, Nielsen T, Buller R, Moltke I, Vitezic M, Albrechtsen A   Read publication   Neuropsychopharmacology
A Noninterventional Cohort Study Assessing Time to All-Cause Treatment Discontinuation After Initiation of Aripiprazole Once-Monthly or Daily Oral Atypical Antipsychotic Treatment in Patients With Schizophrenia   Aripiprazole   Such P, Bøg M, Kabra M, Jørgensen KT, de Jong-Laird AC    Read publication   The Primary Care Companion for CNS Disorders
Adherence and persistence among patients with major depressive disorder enrolled in the vortioxetine tAccess patient support program   Vortioxetine   Lawrence D, Manjelievskaia J, Chrones L, McCue M, Touya M   Read publication   Current Medical Research & Opinion
Agitation in dementia: real-world impact and burden on patients and the healthcare
system
  Brexpiprazole   Jones E, Aigbogun MS, Pike J, Berry M, Houle CR, Husbands J   Read publication   Journal of Alzheimer's Disease
An alternative start regimen with aripiprazole once-monthly in patients with
schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection
  Aripiprazole   Wang Y, Wang X, Harlin M, Larsen F, Panni M, Yildirim M, Madera J, Forbes A, Mustafa N, Ruiz-White I, Raoufinia A   Read publication   Current Medical Research & Opinion
An integrated pharmacokinetic-pharmacodynamic-pharmacoeconomic modelling method to evaluate treatments for adults with schizophrenia   Aripiprazole   Piena M, Houwing N, Kraan C, Wang X, Waters H, Duffy R, Mallikaarjun S, Bennison C   Read publication   PharmacoEconomics
An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy
participants
  Brexpiprazole   Dean F. Wong; Suresh Malikaarjun; Arash Raoufinia; Patricia Bricmont; James R. Brašić; Robert D. McQuade; Robert A. Forbes; Tetsuro Kikuchi; Hiroto Kuwabara   Read publication   European Journal of Clinical Pharmacology
Anti-Aβ antibody Aducanumab regulates the proteome of senile plaques and closely
surrounding tissue in a transgenic mouse model of Alzheimer’s disease
  N/A   Bastrup J, Hansen K, Poulsen T, Kastaniegaard K, Asuni AA, Christensen S, Belling D, Stensballe A, Volbracht C   Read publication   Journal of Alzheimer's Disease
Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: Associations with clinical and treatment outcomes in the AtWoRC
Study
  Vortioxetine   Chokka P, Ge H, Bougie J, Ettrup A, Clerzius G   Read publication   Therapeutic Advances in Psychopharmacology
Are self-reported and self-monitored adherence good proxies for reaching relevant plasma concentrations? Experiences from a study of anti-depressants in healthy volunteers   Vortioxetine   Larsen KG, Areberg J, Åström DO   Read publication   Clinical Trials
Branning et al. Mental Illness Disclosure in the Workplace: An Opportunity for Improvement. American Health and Drug Benefits   Brexpiprazole   Branning G; Waters HC; Houle CR; Worthy S; Fink B; Hayes K     Read publication   -
Brexpiprazole blocks Posttraumatic stress disorder-like memory and promotes normal fear memory   Brexpiprazole   Ducourneau E-G, Guette C, Perrot D, Mondesir M, Mombereau C, Arnt J, Desmedt A, Piazza P-V   Read publication   Molecular Psychiatry
Cardiovascular Outcomes in Adults With Migraine Treated With Eptinezumab for Migraine Prevention: Pooled Data From Four Double-Blind, Randomized, Placebo-Controlled Studies   Eptinezumab   Smith T, Spierings E, Cady R, Hirman J, Ettrup A, Shen V.   Read publication
  -
Changes in antidepressant therapy should be considered early in patients with inadequate response to a first-line agent   Vortioxetine   Bernhard T Baune, Falkai P   Read publication   Australian and New Zealand Journal of Psychiatry
Characterization of the changes in supine blood pressure with long-term use of droxidopa in patients with neurogenic orthostatic hypotension   Droxidopa   Hewitt LA, Lindsten A, Gorny S, Karnik-Henry M, Kymes S, Favit A   Read publication   -
Chronobiologic parameter changes in patients with major depressive disorder and sleep disturbance treated with adjunctive brexpiprazole: an open-label,
flexible-dose, exploratory substudy
  Brexpiprazole   Krystal AD, Mittoux A, Lindsten A, Baker RA   Read publication   Journal of Affective Disorders
Clinical immunogenicity evaluation of Eptinezumab, a therapeutic humanized monoclonal antibody for the preventive treatment of migraine   Eptinezumab   Pederson S, Biondi D, Allan B, Cady R, Schaeffler B, Baker B, Latham J   Read publication   Frontiers in Immunology
Design and Synthesis of Pyrrolo[2,3 d]pyrimidine-derived Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors using a Checkpoint Kinase 1 (CHK1)-derived
Crystallographic Surrogate
  N/A   Williamson D, Smith G, Mikkelsen G, Jensen T, Acheson-Dossang P, Badolo L, Bedford S, Chell V, Jen Chen I, Dokurno P, Hentzer M, Newland S, Ray S, Shaw T, Surgenor A, Terry L, Wang Y, Christensen K   Read publication   Journal of Medicinal Chemistry
Droxidopa persistence in neurogenic orthostatic hypotension may be affected by titration approach   Droxidopa   F Amjad, B Polenchar, A Favit   Read publication   International Journal of General Medicine
Early improvement with vortioxetine predicts response and remission: a post hoc analysis of data from a clinical trial conducted in Japan   Vortioxetine   Inoue T, Fujimoto S, Marumoto T, Kitagawa T, Ishida K, Nakajima T, Moriguchi Y, Fujikawa K, Watanabe K   Read publication   -
Effectiveness of vortioxetine on emotional blunting in patients with major depressive
disorder with inadequate response to SSRI/SNRI treatment
  Vortioxetine   Fagiolini A, Florea I, Loft H, Christensen MC   Read publication   Journal of Affective Disorders
Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews   Brexpiprazole   Weiss C, Meehan SR, Brown TM, Gupta C, Mørup MF, Thase ME, McIntyre RS, Ismail Z   Read publication   -
Effects of brexpiprazole across symptom domains in patients with schizophrenia: post hoc analysis of short- and long-term studies   Brexpiprazole   Marder S, Meehan SR, Weiss C, Chen D, Hobart M, Hefting N   Read publication   Schizophrenia Bulletin
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial   Eptinezumab   Winner P, McAllister P, Chakhava G, Ailani J, Ettrup A, Josiassen MK, Lindsten A, Mehta L, Cady R   Read publication   JAMA: Journal of the American Medical Association
Efficacy of vortioxetine on anhedonia: results from a pooled analysis of short-term studies in patients with major depressive disorder   Vortioxetine   McIntyre R, Loft H, Christensen MC   Read publication   Neuropsychiatric Disease and Treatment
Establishment of a Human Induced Pluripotent Stem Cell Neuronal Model for Identification of Modulators of α-Synuclein Levels and Aggregation   N/A   Vajhøj C, Schmid B, Bousset L, Melki R, Fog K, Holst B, Stummann TC   Read publication   -
Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review   Brexpiprazole   Brockbank J, Krause T, Moss E, Milthers Pedersen A, Frank Mørup M, Ahdesmäki O, Vaughan J, Brodtkorb T-H   Read publication   Health and Quality of Life Outcomes
Impact of Agitation in Long-Term Care Residents with Dementia in the United States   Brexpiprazole   Fillit H, Aigbogun MS, Gagnon-Sanschagrin P, Cloutier M, Davidson M, Serra E, Guérin A, Baker RA, Houle CR, Grossberg G   Read publication   International Journal of Geriatric Psychiatry
In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole   Brexpiprazole   Sasabe H, Koga T, Furukawa M, Matsunaga M, Sasahara K, Nemoto H, Hashizume K, Ohzone Y, Amunom I, Torii M, Umehara K, Kashiyama E, Takeuchi K    Read publication   Xenobiotica
In vivo and in vitro pharmacokinetic characterization of a novel serotonin-dopamine activity modulator brexpiprazole and a main metabolite in rat, monkey and
human
  Brexpiprazole   Sasabe H, Koga T, Furukawa M, Matsunaga M, Kaneko Y, Koyama N, Hirao Y, Akazawa H, Kawabata M, Kashiyama E, Takeuchi K.   Read publication   Xenobiotica
Incremental burden of comorbid major depressive disorder in patients with type 2 diabetes or cardiovascular disease: a retrospective claims analysis   Vortioxetine   Kangethe A, Lawrence DF, Touya M, Chrones L, Polson M, Evangelatos T   Read publication   BMC Health Services Research
Long-term safety and tolerability of eptinezumab in patients with chronic migraine: A 2-year, open-label, phase 3 trial   Eptinezumab   Kudrow D, Cady R, Allan B, Pederson S, Hirman J, Mehta L., Schaeffler B.   Read publication   BMC Neurology
Management of Neurogenic Orthostatic Hypotension in Neurodegenerative Disorders: A Collaboration Between Cardiology and Neurology   Droxidopa   F Amjad, S Beinart   Read publication   Neurology and Therapy
Management Strategies for Comorbid Supine Hypertension in Patients With Neurogenic Orthostatic Hypotension   Droxidopa   Isaacson S, Dashtipour K, Mehdirad A, Peltier A   Read publication   Current Neurology and Neuroscience Reports
Monoacylglycerol lipase inhibition in Tourette syndrome. A 12-week randomized, placebo-controlled, study with Lu AG06466   N/A   Kirsten R. Müller-Vahl, Carolin Fremer, Chan Beals, Jelena Ivkovic, Henrik Loft and Christoph Schindler   Read publication   -
New Drug and Biologics Approvals in 2019: A Systematic Analysis of Patient Experience
Data in FDA Drug Approval Packages and Product Labels
  N/A   Schultz-Knudsen K, Sabaliauskaite U, Hellsten J, Blaedel Lassen A, Vinther Morant A   Read publication   Therapeutic Innovation & Regulatory Science
Nonclinical safety evaluation, pharmacokinetics and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies   N/A   Fjord-Larsen L, Thougaard A, Wegener KM, Christensen J, Larsen F, Schrøder-Hansen LM, Kaarde M, Ditlevsen D   Read publication   -
Online Survey of Clinical Practice in Patients with Schizophrenia Treated with
Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
  Aripiprazole   Such P, Olivares JM, Arias L, Berg MT, Madera J    Read publication   Neuropsychiatric Disease and Treatment
Patient and physician perspectives of depressive symptoms and expectations for
treatment outcome: results from a web-based survey
  Vortioxetine   Ishigooka J, Hoshino T, Imai T,Yoshida H, Ono M, Ota M, Moriguchi Y, Fujikawa K, Shintani A, Fernandez J   Read publication   Neuropsychiatric Disease and Treatment
Patient expectations and experience of the early phases of antidepressant therapy for
major depressive disorder: A qualitative study
  Vortioxetine   Baune BT, Florea I, Ebert B, Touya M, Ettrup A, Hadi M, Ren H    Read publication   Neuropsychiatric Disease and Treatment
Patient-Identified Most Bothersome Symptom in Preventive Migraine Treatment With Eptinezumab: A Novel Patient Centered Outcome   Eptinezumab   Lipton R, Dodick D, Ailani J, McGill L, Hirman J, Cady R   Read publication   Headache: The Journal of Head and Face Pain
Personalized prediction of progression in pre-dementia patients based on individual biomarker profile: A development and validation study   N/A   Kühnel L, Bouteloup V, Lespinasse J, Chêne G, Dufouil C, Raket LL   Read publication   -
Phosphodiesterase type 1 inhibition Alters medial prefrontal cortical activity and
reward-driven behaviour and Partially reverses neurophysiological deficits in
the rat phencyclidine model of schizophrenia
  N/A   Hayes J, Laursen B, Eneberg E, Kehler J, Rasmussen L, Langgard M, Bastlund J,
Gerdjikov T
  Read publication   Neuropsychopharmacology
Pooled analysis of safety information of clinical trials of vortioxetine including Japanese patients with major depressive disorder   Vortioxetine   Osawa M, Nakajima T, Fujimoto S, Ogino Y, Moriguchi Y, Takeshi I   Read publication   -
Predicting time to relapse in patients with schizophrenia according to patients’ relapse history: a historical cohort study using real-world data in Sweden   Brexpiprazole   Jørgensen KT, Bøg M,Kabra M, Simonsen J, Adair M, Jönsson L     Read publication   -
Predictors and trajectories of treatment response to SSRIs in patients suffering from
PTSD
  Brexpiprazole   Anne Krogh Nøhr, Hans Eriksson, Mary Hobart, Ida Moltke, Raimund Buller, Anders Albrechtsen, Stinus Lindgreen   Read publication   Psychiatry Research
Predictors of persistence in patients with schizophrenia treated with aripiprazole
once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study
  Aripiprazole   Olivares JM, González-Pinto A, Páramo M   Read publication   European Psychiatry
Prevalence of post-traumatic stress disorder in the United States: a systematic literature review   Brexpiprazole   Schein J, Houle CR, Urganus AL, Jones E, Pike J, Husbands J, Willey CJ   Read publication   -
Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache   Eptinezumab   Marmura MJ, Diener HC, Cowan RP, Tepper SJ, Diamond ML, Starling AJ, Hirman J, Mehta L, Brevig T, Cady R   Read publication   Headache: The Journal of Head and Face Pain
Quantification of in vivo metabolic activity of CYP2D6 genotypes and alleles through
population pharmacokinetic analysis of vortioxetine
  Vortioxetine   Frederiksen T, Areberg J, Schmidt E, Stage TB, Brosen K   Read publication   Clinical Pharmacology & Therapeutics
Redefining Expectations for Migraine Prevention   Eptinezumab   Cady R, Gottschalk C, Pavlovic J   Read publication   US Neurology
Relationship of subjective cognitive impairment with psychosocial function and relapse of depressive symptoms in patients with major depressive disorder: analysis of
longitudinal data from PERFORM-J
  Vortioxetine   Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Hammer-Helmich L, Fernandez J   Read publication   Neuropsychiatric Disease and Treatment
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials   Eptinezumab   Smith T, Spierings E , Cady R, Hirman J, Schaeffler B, Werther S, Shen V, Spierling B, Brevig T, Josiassen M,  Brunner E, Mehta L, Honeywell L   Read publication   The Journal of Headache and Pain
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: a post-hoc analysis of a long-term open label study   Brexpiprazole   Ishigooka J, Inada K, Niidome K, Aoki K, Kijima Y, Iwashita S, Yamada S   Read publication   Human Psychopharmacology: Clinical and Experimental, Psychiatry and Clinical
Neurosciences
Schein et al. Prevalence of post-traumatic stress disorder in the United States: A systematic literature review   Brexpiprazole   Schein J, Houle C, Urganus A, Cloutier M, Patterson-Lomba O, Wang Y, King S, Levinson W, Guerin A, Lefebvre P, Davis LL   Read publication   Current Medical Research & Opinion
Simultaneous Modelling of Alzheimer’s Disease Progression via Multiple Cognitive Scales   N/A   Kühnel L, Berger A-K, Markussen B,  Raket L   Read publication   Statistics in Medicine
Systemic administration of Ivabradine, an HCN channel inhibitor, blocks spontaneous absence seizures   N/A   Iacone Y, Morais T, David F, Delicata F, Parri R, Weisser J, Bundgaard C, Vestergaard Klewe I, Thomsen M, Crunelli V, Lőrincz M   Read publication   Epilepsia
The Eptinezumab:CGRP Complex Structure: The Role  of Conformational Changes in Binding Stabilization   Eptinezumab   Laurent D, Scalley Kim M, Olland A, White A, Misura K,     Read publication   -
Therapeutic potential of vortioxetine for anxious depression: a post hoc analysis of data from a clinical trial conducted in Japan   Vortioxetine   Inoue T, Fujimoto S, Marumoto T, Kitagawa T, Ishida I, Nakajima T, Moriguchi Y, Fujikawa K, Watanabe K   Read publication   -
Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients   Eptinezumab   Baker B, Schaeffler B, Hirman J, Hompesch M, Peterson S, Smith J   Read publication   Endocrinology, Diabetes & Metabolism
Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection   Aripiprazole   Fitzgerald HM, Shepherd J, Bailey H, Berry M, Wright J, Chen M   Read publication   Neuropsychiatric Disease and Treatment
Two randomized, placebo-controlled double-blind trials and one open-label long-term trial of brexpiprazole for the acute treatment of bipolar mania   Brexpiprazole   Eduard Vieta, Gary Sachs, Denise Chang, Johan Hellsten, Claudette Brewer, Tim Peters Strickland, Nanco Hefting   Read publication   Journal of Psychopharmacology
Using the goal attainment scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open label, multicenter study   Vortioxetine   McCue M, Sarkey S, Eramo A, François C, Parikh SV   Read publication   BMC Psychiatry
Validation of a population pharmacokinetic model of vortioxetine using therapeutic drug monitoring data   Vortioxetine   Frederiksen T, Smith RL, Wollmann BM, Areberg J, Molden E     Read publication   -
Validation of the oxford depression questionnaire: sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting   Vortioxetine   Christensen MC, Fagiolini A, Florea I, Loft H, Cuomo A, Goodwin G   Read publication   Journal of Affective Disorders Reports
Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety and optimal timing of dose adjustment   Vortioxetine   Christensen MC, McIntyre RS, Florea I, Loft H, Fagiolini A   Read publication   CNS Spectrums

 

Article       Product      Authors      Publication links      Journal
A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study   Vortioxetine   Jacobsen P, Zhong W, Xu R, Nomikos G   Read publication   Journal of Affective Disorders
A PET Occupancy Study of Brexpiprazole at Dopamine D2 and D3 Receptors, Serotonin 5-HT1A and 5-HT2A Receptors, and Serotonin Reuptake Transporters in Subjects With Schizophrenia   Brexpiprazole   Girgis R, Abi-Dargham A, Forbes, A, Slifstein M   Read publication   Neuropsychopharmacology
A Questionnaire-Based Evaluation of the Attitude of European Physicians towards the Use of Antipsychotic Long-Acting Injectables   Aripiprazole   Heres S, Patel M, Bent-Ennakhil N, Sapin C, di Nicola S   Read publication   BMC Psychiatry,European Neuropsychopharmacology
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder   Vortioxetine   Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I   Read publication   Rinsho Yakuri (Japanese Journal of Clinical Pharmacology)
Cardiovascular Disorders Mediated by Autonomic Nervous System Dysfunction   Droxidopa   Mehdirad A, Khemani P   Read publication   Cardiology in Review
Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram   Vortioxetine   Jacobsen PL, Zhong W, Nomikos GG, Affinito J, Cutler AJ, Clayton    Read publication   CNS Spectrums
Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine   Eptinezumab   Houts, C, Wirth R, McGinley J, Cady R, Lipton R,   Read publication   Headache: The Journal of Head and Face Pain
Effect of brexpiprazole on impulsivity in schizophrenia: a task-based functional magnetic resonance imaging study   Brexpiprazole   van Erp TGM, Baker RA, Cox K, Okame T, Kojima Y, Eramo A, Potkin SG   Read publication   Psychiatry Research: Neuroimaging 
Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma   Vortioxetine   Christensen MC, Florea I, Loft H, McIntyre RS   Read publication   Journal of Affective Disorders
Efficacy, Tolerability, and Safety of Eptinezumab in Patients with a Dual Diagnosis of Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2   Eptinezumab   Diener HC, Marmura M, Tepper S, Cowan R, Starling A, Diamond M, Hirman J, Mehta L, Brevig T, Sperling B, Cady R   Read publication   Headache: The Journal of Head and Face Pain
Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing   Eptinezumab   Dodick D, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S        
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 study   Eptinezumab   Silberstein S, Diamond M, Hindiyeh N, Biondi D, Cady R, Hirman J, Allan B, Pederson S, Schaeffler B, Smith J,   Read publication   The Journal of Headache and Pain
Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study   Eptinezumab   Smith T, Janelidze M, Chakhava G, Cady R, Hirman J, Allan B, Pederson S,Smith J, Schaeffler B,   Read publication   Clinical Therapeutics
Eptinezumab in episodic migraine: The randomized, double-blind, placebo-controlled PROMISE-1 study   Eptinezumab   Ashina M, Saper J, Cady R, Schaeffler B, Biondi D, Hirman J, Pederson S, Allan B, Smith J   Read publication   Cephalalgia
Impact of atypical antipsychotics as adjunctive therapy on psychiatric cost and utilization in patients with major depressive disorder   Brexpiprazole    Yan T, Greene M, Chang E, Houle C, Tarbox M, Broder MS   Read publication   ClinicoEconomics and Outcomes Research
Impact of cognitive symptoms on health-related quality of life and work productivity in Chinese patients with major depressive disorder: results from the PROACT study   Vortioxetine   Wang G, Tan KHX, Ren H, Hammer-Helmich L   Read publication   Neuropsychiatric Disease and Treatment
Improvements in workplace productivity in working patients with major depressive disorder: results from the AtWoRC study   Vortioxetine   Chokka P, Bougie J, Tvistholm AH, Clerzius G, Ettrup A   Read publication   Journal of Occupational and Environmental Medicine
Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: A 7-day randomized, double-blind, placebo-controlled exploratory study   Vortioxetine   Rancans E, Zambori J, Dalsgaard M, Baayen C, Areberg J, Ettrup A, Florea I   Read publication   International Clinical Psychopharmacology
Neurobiology of TRS: Research Roadmap   Lu AF35700   Kane J, Potkin S, Correll C, Agid O, Olfson M, Lindenmayer JP, Marder S, Howes O   Read publication   npj Schizophrenia
Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls   Droxidopa   LeWitt P, Kymes S, Hauser R   Read publication   Aging and Disease
Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine   Droxidopa   Mobarek S   Read publication    
Pharmacologic Characterization of ALD403, a Potent Neutralizing Humanized Monoclonal Antibody Against the Calcitonin Gene-Related Peptide   Eptinezumab   Garcia-Martinez L, Raport C, Ojala E, Dutzar B, Anderson K, Stewart E, Kovacevich B, Baker B, Billgren J, Scalley-Kim M, Karasek C, Allison D, Latham J   Read publication   Journal of Pharmacology and Experimental Therapeutics
Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine   Eptinezumab   Baker B, Schaeffler B, Beliveau M, Rubets I       Pharmacology Research & Perspectives
Post hoc analysis of a randomized, placebo-controlled, active-reference 6-week study of brexpiprazole in patients with acute schizophrenia   Brexpiprazole   Marder SR, Eriksson H, Zhao Y, Hobart M   Read publication   Acta Neuropsychiatrica
Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study   Brexpiprazole   Ishigooka J, Usami T, Iwashita S, Kojima Y, Matsuo S        
PROMISE–2: Efficacy and safety of eptinezumab in patients with chronic migraine   Eptinezumab   Lipton R, Goadsby P, Smith J, Schaeffler B, Biondi D,  Hirman J, Pederson S, Allan B, Cady R   Read publication   Neurology
Psychiatric Cost in Patients with Schizophrenia Treated with Oral Atypical Antipsychotic Therapy   Brexpiprazole 
  Yan T, Greene M, Chang E, Houle C, Waters HC, Tarbox M, Broder MS   Read publication   Clinical Therapeutics
Real-World Droxidopa or Midodrine Treatment Persistence  in Patients With Neurogenic Orthostatic Hypotension  or Orthostatic Hypotension   Droxidopa   Kymes S, Jackson K, Sullivan, C, Raj S   Read publication   Autonomic Neuroscience: Basic & Clinical
Real-World Patient Experience with Sexual Dysfunction and Antidepressant use in Depressed Patients: A Cross-Sectional Survey Study   Vortioxetine   Paula L. Jacobsen, Eileen M. Thorley, Christopher Curran, Emil Chiauzzi   Read publication   Neurology, Psychiatry and Brain Research
Reliability and validity of the 6‑item Headache Impact Test in chronic migraine from the PROMISE‑2 study   Eptinezumab   Houts CR, McGinley JS, C, Wirth RJ, Cady R, Lipton RB,   Read publication   Quality of Life Research
Risk of major depressive disorder in Japanese cancer patients: A matched cohort study using employer-based health insurance claims data   Vortioxetine   Akechi T, Mishiro I, Fujimoto S, Murase K   Read publication   Psycho-Oncology
Risk of major depressive disorder in spouses of cancer patients in Japan: a cohort study using health-insurance based claims data   Vortioxetine   Akechi T, Mishiro I, Fujimoto S, Murase K   Read publication   Psycho-Oncology
Successfully treated patients with vortioxetine versus venlafaxine: A simplified cost-effectiveness analysis in Asian patients with major depressive disorder   Vortioxetine   Wang G, Zhao K, Reynaud-Mougin C, Loft H, Ren H, Eriksen H-LF, Ettrup A   Read publication   Current Medical Research & Opinion
Symptoms of major depressive disorder and psychosocial functioning in the different phases of the disease: does the perspective of patients and healthcare providers differ?   Vortioxetine   Christensen MC, Wong J, Baune BT   Read publication   Frontiers in Psychiatry
The Impact of the Food and Drug Administration Antipsychotic Drug Boxed Warning on Psychiatric Medication Use, Health Events, and Quality of Life in Elderly Dementia Patients   Brexpiprazole    Annalisa Rubino, Myrlene Sanon, Michael Ganz, Alex Simpson, Miram Fenton, Sumit Verma, Ann Hartry, Ross Baker, Ruth Duffy, Keva Gwin, Howard Fillit    Read publication   JAMA Network Open
The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: A report on global assessment of functioning and the WHO wellbeing index   Aripiprazole   Schöttle D, Janetzky W, Luedecke D, Beck E, Correll CU, Wiedemann K
  Read publication   BMC Psychiatry
Treatment of major depressive disorder in Japanese patients with cancer: a matched cohort study using employer-based health insurance claims data   Vortioxetine   Akechi T, Fujimoto S, Mishiro I, Murase K
  Read publication   Clinical Drug Investigation
Using self-reported vocational functioning measures to identify working patients with impaired functional capacity in major depressive disorder   Vortioxetine   Murthy V, Xu R, Zhong W, Harvey P   Read publication   Journal of Affective Disorders

 

Article  Product Authors Publication links Journal
6-Month Use of Droxidopa for Neurogenic Orthostatic Hypotension
Droxidopa Francois C, Shibao CA, Biaggioni I, Duhig AM, McLeod K, Ogbonnaya A, Quillen A, Cannon J, Padilla C, Kymes S, Yue B Read publication Movement Disorders Clinical Practice
A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as adjunctive therapy in adults with major depressive disorder Brexpiprazole  Hobart M, Zhang P, Brewer C, Hefting N Read publication Journal of Clinical Psychopharmacology
A new principal stratum estimand investigating the treatment effect in patients who would comply, if treated with a specific treatment Brexpiprazole  Groes Larsen K, Krog Josiassen M Read publication Statistics in Biopharmaceutical Research
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder Vortioxetine Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I Read publication Psychiatry and Clinical Neurosciences
A Systematic Literature Review Identifying Associations Between Outcomes and Quality of Life (QoL) or Health Care Resource Utilisation (HCRU) in Schizophrenia Lu AF35700 Germain N, Weatherall J, Kymes S, Löf E, Jakubowska A, François C Read publication Journal of Medical Economics
Adapting the goal attainment approach for major depressive disorder Vortioxetine McCue M, Parikh S, Mucha L, Sarkey S, Cao C, Eramo A, Opler M, Lind B, Francois C Read publication Neurology and Therapy
Agitation in patients with dementia: a systematic review of epidemiology and association with severity and course Brexpiprazole  Anatchkova M, Brooks A, Swett L, Hartry A, Duffy RA, Baker RA, Hammer-Helmich L, Sanon Aigbogun M Read publication International Psychogeriatrics 
Anti-tau antibody-mediated clearance in mouse microglia cultures requires Fcγ-receptor interaction and functional lysosomes AF87908 Tau Andersson CR, Falsig J, Stavenhagen JB, Christensen S, Kartberg F, Rosenqvist N, Finsen B, Pedersen JT Read publication Scientific Reports
Assessment of current clinical practices for major depression in Japan using a web-based questionnaire Vortioxetine Hori H, Kentaro Y Read publication Neuropsychiatric Disease and Treatment
Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5-HT2A receptors in rats Brexpiprazole  Amada N, Akazawa H, Ohgi Y, Maeda K, Sugino H Kurahashi N, Kikuchi T, Futamura T Read publication Neuropsychopharmacology Reports
Burden of Care for Treatment-Resistant Schizophrenia: A Quantitative Caregiver Survey of Experiences, Attitudes and Perceptions Lu AF35700 Velligan D, Brain C, Bouérat Duvold L, Agid O, Read publication Frontiers in Psychiatry
Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine Vortioxetine

Lachaine J, Beauchemin C, Bibeau J,

Patenaude J, Chokka P, Proulx J, Bougie J 

Read publication CNS Spectrums
Characteristics, Burden and Pharmacotherapy of Treatment-Resistant Schizophrenia: Results From a Survey of 204 US Psychiatrists Lu AF35700 Correll CU, Brevig T, Brain C Read publication BMC Psychiatry
Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia Lu AF35700 Agid O, Baldwin M, Correll C, Howes O, Kane J, Lindenmayer JP, Marder S, Olfson M, Potkin S Read publication Journal of Clinical Psychiatry
Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram Vortioxetine Jacobsen PL, Zhong W, Nomikos GG, Affinito J, Cutler AJ, Clayton  Read publication CNS Spectrums
Cognitive symptoms in major depressive disorder: Associations with clinical and functional outcomes in a 6-month, non-interventional, prospective study in China Vortioxetine Wang G, Si T-M, Li L-J, Fang Y-R, Wang C-X, Wang L-N, Tan K H X, Ettrup A; Eriksen F H-L, Luo S, Ge L Read publication Neuropsychiatric Disease and Treatment
Comparisons of Global Tests on Intersection Hypotheses and Their Application in Matched Parallel Gatekeeping Procedures Brexpiprazole  Ouyang J, Zhang P, Carroll KJ, Lee J, Koch G Read publication Journal of Biopharmaceutical Statistics
Creation and validation of a linear index to measure the health state of patients with depression in automated healthcare databases Vortioxetine Touya M, Lamy FX, Tanaescu A, Saragoussi D, Francois C, Wade A, Llorca PM, Lancon C, Falissard B Read publication Journal of Market Access & Health Policy
Development of a Classifier to Identify Patients with Probable Lennox–Gastaut Syndrome in Health Insurance Claims Databases Via Random Forest Methodology Clobazam Vekeman F, Piña-Garza JE, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Duh MS, Shen V, Saurer TB, Montouris GD, Isojarvi J Read publication Current Medical Research & Opinion
Differences in perceptions of major depressive disorder symptoms and treatment priorities between patients and health care providers across the acute, post-acute, and remission phases of depression Vortioxetine Baune B, Christensen MC Read publication Frontiers in Psychiatry
Drug-Drug Interactions With Concomitant Clobazam and Cannabidiol Usage in Refractory Seizures Clobazam Tolbert D, Klein P, Gidal B Read publication Epilepsy & Behavior 
Early Initiation of Long-Acting Injectable Antipsychotic Treatment is Associated with Lower Hospitalization Rates and Healthcare Costs in Patients with Schizophrenia: Real-World Evidence From US Claims Data Aripiprazole Munday J, Broder MS, Chang E, Hartry A, Yan TJ, Greene M
Read publication
Current Medical Research & Opinion
Economic burden of relapse/recurrence in patients with major depressive disorder Vortioxetine Gauthier G, Mucha L, Shi S, Guerin A Read publication Journal of Drug Assessment
Effect of brexpiprazole on agitation and hostility in patients with acute schizophrenia Brexpiprazole  Citrome L, Ouyang J, Meehan SR, Baker RA, Weiss C Read publication Journal of Clinical Psychopharmacology
Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain Vortioxetine Yang K-C, Stepanov V, Amini N, Martinsson S, Takano A, Bundgaard C, Bang-Andersen B, Sanchez C, Halldin C, Farde L, Finnema SJ Read publication Neuropsychopharmacology
Effects of vortioxetine and escitalopram on electroencephalographic recordings – A randomized, crossover trial in healthy males Vortioxetine Nissen TD, Laursen B, Viardot G, l´Hostis P, Danjou P, Sluth LB, Gram M, Bastlund JF, Christensen SR, Drewes AM Read publication Neuroscience
Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis Vortioxetine Jacobson W, Harvey P, Zhong W, Nomikos G, Olsen CK, Christensen M Read publication Current Medical Research & Opinion
Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies Brexpiprazole  Thase M, Hobart M, Zhang P, Weiss C, Meehan SR Read publication Expert Opinion on Pharmacotherapy
Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials Brexpiprazole  Grossberg G, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, Slomkowski M, Baker RA, McQuade R, Cummings J Read publication American Journal of Geriatric Psychiatry
Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma Vortioxetine Christensen MC, Florea I, Loft H, McIntyre RS Read publication Journal of Affective Disorders
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial Eptinezumab Dodick DW, Lipton RB, Silberstein S, Goadsby P4, Biondi D, Hirman J, Cady R, Smith J Read publication Cephalalgia
Exploration of treatment-resistant schizophrenia subtypes based on a survey of 204 US psychiatrists Lu AF35700 Correll CU, Brevig T, Brain C Read publication Neuropsychiatric Disease and Treatment
Health-related quality of life outcomes, economic burden and cost associated among diagnosed and undiagnosed depression patients in Japan Vortioxetine Yamabe K, Liebert R, Flores N Read publication ClinicoEconomics and Outcomes Research
Identifying and Characterizing Treatment-Resistant Schizophrenia in Observational Database Studies Lu AF35700 Jonsson L, Simonsen J, Brain C, Kymes S, Watson L Read publication International Journal of Methods in Psychiatric Research
Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: A 2-week, randomized, double-blind, placebo-controlled study Vortioxetine Vieta E, Florea I, Schmidt S N, Areberg J, Ettrup A Read publication International Clinical Psychopharmacology
Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder: results from the AtWoRC study Vortioxetine Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A Read publication CNS Spectrums
Management of Coexistent Neurogenic  Orthostatic Hypotension and Supine Hypertension Droxidopa Cannom D Read publication Journal of Clinical Hypertension
Management of Depression in Adolescents in Japan Escitalopram Saito T, Reines E, Florea I, Dalsgaard M Read publication Journal of Child and Adolescent Psychopharmacology
Medication adherence, health service use, and costs in patients with major depressive disorder initiating adjunctive antipsychotic treatment Brexpiprazole  Broder MS, Greene M, Yan T, Chang E, Hartry A, Yermilov I Read publication Clinical Therapeutics
Neurogenic Orthostatic Hypotension: A Nonmotor Symptom of Parkinson Disease Droxidopa Low P, Cutsforth-Gregory J Read publication Neurology and Therapy
Open-label, Multicenter, Phase 3 Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-moderate Alzheimer’s Disease Idalopirdine Frölich L, Alireza A, Ballard C, Tariot P, Molinuevo JL, Boneva N, Geist M, Raket L, Cummings J  Read publication Journal of Alzheimer's Disease
Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls Droxidopa LeWitt P, Kymes S, Hauser R Read publication Aging and Disease
Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial Vortioxetine Jacobsen P, Zhong W, Nomikos G, Clayton A Read publication The Journal of Sexual Medicine
Patient attitudes towards and goals for MDD treatment: A survey study Vortioxetine McNaughton E, Granskie J, Curran C, Opler M, Sarkey S, Mucha L, Eramo A, Francois C, Webber-Lind B, McCue M Read publication Patient Preference and Adherence
Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study Vortioxetine Haro JM, Hammer-Helmich L, Saragoussi D, Ettrup A, Larsen KG Read publication Neuropsychiatric Disease and Treatment
Pharmacokinetics and safety of vortioxetine in the Chinese population Vortioxetine Miao J, Wang G, Hou J, Areberg J, Zhao Y,  Højer AM, Ettrup A Read publication Advances in Therapy
Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide Eptinezumab Moldovan Loomis C, Dutzar B, Ojala EW, Hendrix L, Karasek C, Scalley-Kim M, Mulligan J, Fan P, Billgren J, Rubin V, Boshaw H, Kwon G, Marzolf S, Stewart E, Jurchen D, Pederson SM, Perrino McCulloch L, Baker B, Cady RK, Latham JA, Allison D, Garcia-Martinez LF Read publication Journal of Pharmacology and Experimental Therapeutics
Pharmacometrics of Clobazam in Pediatrics: Prediction of Effective Clobazam Doses for Dravet Syndrome Clobazam Tolbert D, Chu H-M, Ette EI Read publication Epilepsy Research
Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis Vortioxetine Liguori C, Ferini-Strambi L, Izzi F, Mari L, Manfredi N, D'Elia A, Mercuri NB, Placidi F Read publication British Journal of Clinical Pharmacology
Psychometric validation of Japanese version of Alcohol Quality of Life Scale (AQoLS) in the treatment of patients with alcohol use disorder – a non-interventional, prospective, longitudinal, multi-site cohort study Nalmefene Higuchi S, Moriguchi Y, Tan KHX Read publication Quality of Life Research
Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study Aripiprazole Mustafa S, Bougie J, Miguelez M, Clerzius G, Rampakakis E, Proulx J, Malla A Read publication BMC Psychiatry
Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder: cross sectional analysis of baseline data from PERFORM-J Vortioxetine Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Tan K, Hammer-Helmich L, Fernandez J Read publication Journal of Affective Disorders
Results and validation of an index to measure health state of patients with depression in automated healthcare databases Vortioxetine Lamy FX, Falissard B, Francois C, Lancon C, Llorca PM, Tanaescu A, Touya M, Verpillat P, Wade A, Saragoussi D Read publication Journal of Market Access & Health Policy
Results of a Real-World Study of Vortioxetine in Patients with Major Depressive Disorder in South East Asia (REVIDA): Subgroup Analysis of Malaysian Patients Vortioxetine Chin CN, Azhar, Au YKC, Chong MSwee Woon, Yen TH, Yeoh BBD, Yap CH, Ku RKA, Keira JH Read publication Malaysian Journal of Psychiatry
Role of Nurses and Nurse Practitioners in the Recognition, Diagnosis, and Management of Neurogenic Orthostatic Hypotension Droxidopa Biswas D, Karabin B, Turner D Read publication International Journal of General Medicine
Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials. Vortioxetine Mahableshwarkar A, Jacobsen P, Affinito J, Reines E, Xu J, Nomikos G Read publication CNS Spectrums
Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies Aripiprazole Madera JJ, Such P, Zhao C, Baker RA Read publication Neuropsychiatric Disease and Treatment
The effect of aripiprazole once monthly on personal and social functioning: Post hoc analyses of acute and long-term studies Aripiprazole Peters-Strickland T, Baker RA, Such P, Zhang P, Madera JJ Read publication Neuropsychiatric Disease and Treatment
The patient perspective on cognitive symptoms in major depressive disorder: a retrospective database and prospective survey analysis Vortioxetine Chiauzzi E, Drahos J, Sarkey S, Curran C, Wang V, Tomori D Read publication Journal of Participatory Medicine
Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine Vortioxetine Nierenberg AA, Loft H, Olsen CK Read publication Journal of Affective Disorders
Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient With Cardiovascular Disease and Parkinson Disease: A Case Report Droxidopa McCullough P Read publication Cardiology and Therapy
Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis Brexpiprazole  Sanon Aigbogun M, Stellhorn R, Hartry A, Baker RA, Fillit H Read publication BMC Neurology
Use of Droxidopa for the Long-Term Treatment of Neurogenic Orthostatic Hypotension Droxidopa Hewitt LA, Raj S Read publication European Heart Journal
Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment Aripiprazole Madera JJ, Such P, Zhang P, Baker RA, Grande I Read publication Neuropsychiatric Disease and Treatment
Using self-reported vocational functioning measures to identify working patients with impaired functional capacity in major depressive disorder Vortioxetine Murthy V, Xu R, Zhong W, Harvey P Read publication Journal of Affective Disorders
Utility of Autonomic Testing for the Efficient Diagnosis and Effective Pharmacologic Management of Neurogenic Orthostatic Hypotension Droxidopa Suleman, A; Bin Alam, S; Almardini W Read publication BMJ Case Reports
Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized double-blind, placebo-controlled proof-of-concept study Vortioxetine Biederman J, Lindsten A, Sluth L B, Petersen M L, Ettrup A, Eriksen H-L F, Fava M Read publication Journal of Psychopharmacology
Wearable Technology for High-Frequency Cognitive and Mood Assessment in Major Depressive Disorder: Longitudinal Observational Study. Vortioxetine Cormack F, McCue M, Taptiklis N, Skirrow C, Glazer E, Panagopoulos E, van Schaik TA, Fehnert B, King J, Barnett JH Read publication JMIR Mental Health